Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL3650 Target Snapshot

Fibroblast growth factor receptor 1 · SINGLE PROTEIN · Homo sapiens

8,313Compounds
1,252Assays
36Approved Drugs
10,681.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Fibroblast growth factor receptor 1 shows approved-linked disease relevance led by neoplasm. 5 more disease programs remain visible in the same review block. 9 linked drugs keep the current disease frame grounded. Protein identity stays anchored to UniProt P11362. Start with neoplasm, then reuse UniProt P11362 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with neoplasm, then reuse UniProt P11362 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13 9 linked drugs
Open source guide
Disease program
neoplasm

Fibroblast growth factor receptor 1 shows approved-linked disease relevance led by neoplasm. 5 more disease programs remain visible in the same review block. 9 linked drugs remain visible in the same block.

Start review with neoplasm because it currently carries approved-linked support. Linked drugs include E-7090, FGFR INHIBITOR DEBIO 1347, HMPL-453, LUCITANIB. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Approved-linked Open Targets-ready proxy 9 linked drugs
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Fibroblast growth factor receptor 1 as ChEMBL target CHEMBL3650, mapped to UniProt P11362. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Fibroblast growth factor receptor 1
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL3650
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P11362
Fibroblast growth factor receptor 1
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Fibroblast growth factor receptor 1 is the right protein anchor across sources, using UniProt P11362 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why neoplasm is currently framed as approved-linked support. It currently carries 9 linked drugs in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelFibroblast growth factor receptor 1
UniProt AccessionP11362
Component TypeProtein
Sequence Length822 aa

Fibroblast growth factor receptor 1

Source · UniProt accession via ChEMBL component mapping
Review Cue

How to read this target

Review this target as Fibroblast growth factor receptor 1, mapped to UniProt P11362. Sequence length is 822 aa.

Mapped IDP11362
Review nameFibroblast growth factor receptor 1
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Approved-linked Open Targets-ready proxy

Fibroblast growth factor receptor 1 shows approved-linked disease relevance led by neoplasm. 5 more disease programs remain visible in the same review block.

Approved-linked Approved
neoplasm
9 linked drugs · 9 direct · 9 efficacy
Linked drugE-7090
Linked drugFGFR INHIBITOR DEBIO 1347
Linked drugHMPL-453
Linked drugLUCITANIB
Approved-linked Approved
cholangiocarcinoma
4 linked drugs · 4 direct · 4 efficacy
Linked drugE-7090
Linked drugHMPL-453
Linked drugPEMIGATINIB
Linked drugREGORAFENIB
Approved-linked Approved
cancer
3 linked drugs · 3 direct · 3 efficacy
Linked drugLUCITANIB
Linked drugPEMIGATINIB
Linked drugREGORAFENIB
Approved-linked Approved
sarcoma
3 linked drugs · 3 direct · 3 efficacy
Linked drugPAZOPANIB HYDROCHLORIDE
Linked drugREGORAFENIB
Linked drugSURUFATINIB
Approved-linked Approved
soft tissue sarcoma
3 linked drugs · 3 direct · 3 efficacy
Linked drugPAZOPANIB HYDROCHLORIDE
Linked drugREGORAFENIB
Linked drugSURUFATINIB
Approved-linked Approved
colorectal cancer
2 linked drugs · 2 direct · 2 efficacy
Linked drugREGORAFENIB
Linked drugSURUFATINIB
Source · ChEMBL drug mechanism + indication proxy
Review Cue

How to read disease relevance

Start review with neoplasm because it currently carries approved-linked support. Linked drugs include E-7090, FGFR INHIBITOR DEBIO 1347, HMPL-453, LUCITANIB. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseaseneoplasm
Strongest levelApproved-linked
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

36
Approved
22
Phase III
46
Phase II
25
Phase I
Assay Mix

Activity Type Distribution

IC508,986.0
KI1,233.0
EC5043.0
KD419.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL5951244 10.0 IC50 0.1 Preclinical
CHEMBL4870179 9.92 IC50 0.12 Preclinical
CHEMBL4862823 9.77 IC50 0.17 Preclinical
CHEMBL5556891 9.74 IC50 0.18 Preclinical
CHEMBL5177696 9.74 IC50 0.18 Preclinical
CHEMBL4557949 9.7 IC50 0.2 Preclinical
CHEMBL4542061 9.7 IC50 0.2 Preclinical
CHEMBL4102642 9.7 IC50 0.2 Preclinical
CHEMBL3827818 9.7 IC50 0.2 Preclinical
CHEMBL3348846 9.7 IC50 0.2 Clinical
Distribution

pChEMBL Value Distribution

405
5.0
528
5.5
539
6.0
1120
6.5
774
7.0
975
7.5
810
8.0
774
8.5
262
9.0
40
9.5
pChEMBL
Approved Drugs

Approved Drugs

CAPIVASERTIB
CHEMBL2325741
Approved 2023
FUTIBATINIB
CHEMBL3701238
Approved 2022
INFIGRATINIB PHOSPHATE
CHEMBL1834657
Approved 2021
INFIGRATINIB
CHEMBL1852688
Approved 2021
PEMIGATINIB
CHEMBL4297522
Approved 2020
FEDRATINIB
CHEMBL1287853
Approved 2019
ERDAFITINIB
CHEMBL3545376
Approved 2019
ENTRECTINIB
CHEMBL1983268
Approved 2019
BRIGATINIB
CHEMBL3545311
Approved 2017
TIVOZANIB
CHEMBL1289494
Approved 2017
LENVATINIB
CHEMBL1289601
Approved 2015
NINTEDANIB ESYLATE
CHEMBL3039504
Approved 2014
NINTEDANIB
CHEMBL502835
Approved 2014
REGORAFENIB
CHEMBL1946170
Approved 2012
CABOZANTINIB
CHEMBL2105717
Approved 2012
AXITINIB
CHEMBL1289926
Approved 2012
PONATINIB
CHEMBL1171837
Approved 2012
VANDETANIB
CHEMBL24828
Approved 2011
PAZOPANIB
CHEMBL477772
Approved 2009
SUNITINIB
CHEMBL535
Approved 2006
DASATINIB
CHEMBL5416410
Approved 2006
SORAFENIB
CHEMBL1336
Approved 2005
Assay Landscape

Assay Landscape

1,252
Total Assays
4,353
Tested Compounds
3
Assay Types
Binding — 1,225 assays, 4,353 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 923 3,210 7.4
assay format 148 296 7.4
cell-based format 147 793 6.5
subcellular format 5 29 6.5
organism-based format 2 25 6.6
Functional — 14 assays, 377 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 11 3 6.7
assay format 3 374 6.0
ADME — 13 assays, 38 compounds
BAO Format Assays Compounds Avg pChEMBL
assay format 7 22 5.2
single protein format 5 16 7.1
cell-based format 1 0

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine